Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct 28;159(8):e54.
doi: 10.1016/j.medcli.2022.04.018. Epub 2022 Jul 20.

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia

[Article in English, Spanish]
Ismael F Aomar-Millán  1 , Juan Salvatierra  2 , Enrique Raya Álvarez  2
Affiliations
Comment

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia

[Article in English, Spanish]
Ismael F Aomar-Millán et al. Med Clin (Barc). .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Cardona-Pascual I., Berlana D., Martínez-Valle F., Campany-Herrero D., Montoro-Ronsano J.B. Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia. Med Clin (Barc). 2022;158:301–307. - PMC - PubMed
    1. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637-1645. - PMC - PubMed
    1. Aomar-Millán I.F., Salvatierra J., Torres-Parejo Ú., Nuñez-Nuñez M., Hernández-Quero J., Anguita-Santos F. Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation. Med Clin (Barc). 2021;156:602–605. - PMC - PubMed
    1. Kotch C., Barrett D., Teachey D.T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15:813–822. - PMC - PubMed
    1. Kyriazopoulou E., Poulakou G., Milionis H., Metallidis S., Adamis G., Tsiakos K., et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27:1752–1760. - PMC - PubMed

Substances